Pharmacokinetic study to optimize the intravesical administration of gemcitabine

BJU International

Volumn 106, Issue 11, 2010, Pages 1652-1656

  Gontero, Paolo ^a   Cattel, Luigi ^a   Paone, Tonia C ^a   Milla, Paola ^a   Berta, Giovanna ^a   Fiorito, Chiara ^a   Carbone, Francesco ^a   Medana, Claudio ^a   Tizzani, Alessandro ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Bladder cancer; gemcitabine; non muscle invasive; pharmacokinetics

Indexed keywords

GEMCITABINE;

ADULT; ARTICLE; BLADDER CANCER; BLADDER MUCOSA; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; PH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TRANSURETHRAL RESECTION;

ADMINISTRATION, INTRAVESICAL; ANTIMETABOLITES, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE; HUMANS; HYDROGEN-ION CONCENTRATION; NEOPLASM INVASIVENESS; TISSUE DISTRIBUTION; URINARY BLADDER NEOPLASMS;

EID: 78649315023     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09496.x     Document Type: Article

References (22)

1. Bergman AM, Pinedo HM, Peters GJ,. Determinants of resistance to 2′,2′ difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002; 5: 19 - 33
2. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22 (Suppl. 11): 3 - 10
3. Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 2002; 20: 3193 - 8
4. Laufer M, Ramalingam S, Schoenberg MP, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 2003; 21: 697 - 703
5. Witjes JA, Van Der Heijden AG, Vriesema JL, et al. Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 2004; 45: 182 - 6
6. De Berardinis E, Antonini G, Peters GJ, et al. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU Int 2004; 93: 491 - 4
7. Palou J, Carcas A, Segarra J, et al. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. J Urol 2004; 172: 485 - 8
8. Serretta V, Galuffo A, Pavone C, Allegro R, Pavone-MacAluso M,. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder: phase I-II study on marker lesion. Urology 2005; 65: 65 - 9
9. Calais da Silva FM, Calais FE,. Phase 2 study 2000 mg of intravesical gemcitabine in marker lesions. Eur Urol 2005; 4 (3) (Suppl.): 222
10. Mack D, Höltl W, Bassi P, et al. The ablative effect of quarter dose bacillus Calmette-Guérin on a papillary lesion of the bladder. J Urol 2001; 165: 401 - 3
11. Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; 24: 2729 - 34
12. Gunelli R, Bercovich E, Nanni O, et al. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. Br J Cancer 2007; 97: 1499 - 504
13. Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 2005; 66: 726 - 31
14. Mattioli F, Curotto A, Manfredi V, et al. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. Anticancer Res 2005; 25: 2493 - 6
15. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248 - 54
16. Yilmaz B, Kadioǧlu YY, Aksoy Y,. Investigation of the pharmacokinetics of gemcitabine and 2′,2′-difluorodeoxyuridine in human plasma by liquid chromatography. Anal Biochem 2004; 332: 234 - 7
17. Xu Y, Keith B, Grem JL,. Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 802: 263 - 70
18. Grossman HB, Schmitz-Dräger B, Fradet Y, Tribukait B,. Use of markers in defining urothelial premalignant and malignant conditions. Scand J Urol Nephrol Suppl 2000; 205: 94 - 104
19. Gontero P, Casetta G, Maso G, et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 2004; 46: 339 - 43
20. Gårdmark T, Carringer M, Beckman E, Malmström PU, Members of the Intravesical Gemcitabine Study Group. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder. Urology 2005; 66: 527 - 30
21. Ueno H, Kiyosawa K, Kaniwa N,. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer 2007; 97: 145 - 51
22. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T,. Cellular pharmacology of gemcitabine. Ann Oncol 2006; 17 (Suppl. 5): v7 - 12